The Effect of Covid-19 on the Disease Course of Multiple Sclerosis :Belgian Lessons Learned From Rocky I to Rocky IV
NCT05403463 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230
Last updated 2022-06-08
Summary
Retrospective observational cohort study. ToFCoMS: two years of follow-up of COVID-19 in MS.
Conditions
Sponsors & Collaborators
-
Marie D'hooghe
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-01
- Primary Completion
- 2022-06-01
- Completion
- 2022-06-01
Countries
- Belgium
Study Locations
More Related Trials
-
COVID-19 and Multiple Sclerosis Disease Modifying Therapies
NCT04863586 ·Status: UNKNOWN
-
ATX-MS-1467 in Multiple Sclerosis
NCT01973491 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853 ·Status: COMPLETED
-
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
NCT06675955 ·Status: RECRUITING ·Phase: PHASE3
-
Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS
NCT05510817 ·Status: RECRUITING ·Phase: NA
-
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975 ·Status: RECRUITING ·Phase: NA
-
A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.
NCT04760990 ·Status: COMPLETED
-
Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis
NCT04834401 ·Status: COMPLETED
-
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
NCT00534261 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of BG00012 in MS
NCT00168701 ·Status: COMPLETED ·Phase: PHASE2
-
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
NCT00484536 ·Status: TERMINATED ·Phase: PHASE2
-
Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients
NCT01658384 ·Status: COMPLETED
-
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
NCT01601119 ·Status: COMPLETED
-
MS Relapses During COVID-19 Pandemic
NCT04858763 ·Status: COMPLETED
-
Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis
NCT03153553 ·Status: COMPLETED ·Phase: NA
-
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
NCT01142583 ·Status: COMPLETED
-
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
NCT06460324 ·Status: COMPLETED
-
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
NCT01433497 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
NCT05949580 ·Status: RECRUITING
-
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
NCT03996291 ·Status: COMPLETED ·Phase: PHASE2
-
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
NCT04355611 ·Status: COMPLETED
-
Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
NCT03552211 ·Status: UNKNOWN
-
Mapping the Longitudinal, Multidimensional Impact of MS in Relation to Variables Indicative of Neurological Reserve
NCT06410326 ·Status: COMPLETED
-
Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis
NCT05033782 ·Status: COMPLETED
-
COMparison Between All immunoTherapies for Multiple Sclerosis.
NCT03193866 ·Status: COMPLETED